Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2023 | $60.00 | Buy | H.C. Wainwright |
| 3/1/2023 | $18.00 | Neutral | Guggenheim |
| 12/20/2021 | $52.00 → $62.00 | Buy | HC Wainwright & Co. |
H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $60.00
Guggenheim initiated coverage of Calliditas Therapeutics AB with a rating of Neutral and set a new price target of $18.00
HC Wainwright & Co. reiterated coverage of Calliditas Therapeutics with a rating of Buy and set a new price target of $62.00 from $52.00 previously